试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
编号:NCT00617656登记状态:提前终止企业 / 申办者:Spanish Lung Cancer Group
药物 / 成分:Cisplatin, Docetaxel、Gemcitabine, Cisplatin、Docetaxel, Cisplatin、Docetaxel
登记的停止原因(原文):No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm over the control arm- would not be confirmed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
编号:NCT00659776登记状态:提前终止企业 / 申办者:Oregon Health and Science University
药物 / 成分:Ferumoxytol
登记的停止原因(原文):Due to staffing shortages and lack of funding during Covid.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
编号:NCT01311713登记状态:提前终止企业 / 申办者:Teva Branded Pharmaceutical Products R&D, Inc.
药物 / 成分:CEP-9722
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate
编号:NCT01996696登记状态:提前终止企业 / 申办者:AHS Cancer Control Alberta
药物 / 成分:Metformin、Placebo
登记的停止原因(原文):Results of interim analysis indicate no statistically significant difference in the primary objective between the two arms at baseline and 12 months of follow-up.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
编号:NCT02152956登记状态:提前终止企业 / 申办者:MacroGenics
药物 / 成分:Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off、Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off、Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off、Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off
登记的停止原因(原文):Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
编号:NCT03151811登记状态:提前终止企业 / 申办者:Oncopeptides AB
药物 / 成分:Melflufen、Pomalidomide、Dexamethasone
登记的停止原因(原文):Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
编号:NCT03444870登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Gantenerumab、Placebo
登记的停止原因(原文):Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery
编号:NCT04220489登记状态:提前终止企业 / 申办者:Jacques E. Chelly
药物 / 成分:Ketamine、Placebo Comparator
登记的停止原因(原文):Study stopped due to unexpected issues surrounding the 2020 COVID-19 pandemic
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
编号:NCT04609579登记状态:提前终止企业 / 申办者:Stingthera, Inc.
药物 / 成分:SNX281、pembrolizumab
登记的停止原因(原文):Sponsor decision (not due to safety concerns)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-30
Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock
编号:NCT05192213登记状态:提前终止企业 / 申办者:Hospital Sirio-Libanes
药物 / 成分:Vitamin C、Placebo
登记的停止原因(原文):In order to preserve the safety of the patients and prevent any harm from occurring, we opted to discontinue the study based on previous results (LOVIT study) published at 2022. Were recruited 71 than 1090 participants.
查看官方原始记录 ↗